Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function.
Kaplan
Steven A
SA
Department of Urology, Columbia-Presbyterian Medical Center, New York, New York 10032, USA.
D058891:5-alpha Reductase Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D018340:Receptors, Adrenergic, alpha-1 / Q000145:classification / Q000502:physiology; D012220:Rhinitis / Q000139:chemically induced; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced / Q000209:etiology; D014555:Urination Disorders / Q000209:etiology; D014664:Vasodilation / Q000187:drug effects
D058891:5-alpha Reductase Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018340:Receptors, Adrenergic, alpha-1